

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Thomas Goodwin et al.

Art Unit:

1635

Serial No.:

09/532,001

Examiner:

Karen Lacourciere

Filed:

March 21, 2000

8

Title:

PRODUCTION OF FUNCTIONAL PROTEINS:

BALANCE OF SHEAR STRESS AND GRAVITY

## STATEMENT IN SUPPORT OF REQUEST FOR TRANSFER OF COMPUTER READABLE COPY OF SEQUENCE LISTING IN COMPLIANCE WITH 37 CFR §§ 1.821-1.825, ACCOMPANYING APPLICANT'S RESPONSE TO OFFICE ACTION MAILED MARCH 4, 2002

Assistant Commissioner of Patents Washington, D.C. 20231

Dear Sir:

The paper or compact disc copy of the Sequence Listing submitted in this application, Serial No. 09/532,001, is identical to the computer readable copy of the Sequence Listing filed in application Serial No. 09/056,363, filed on April 7, 1998. In accordance with 37 CFR 1.821(e), please use the first-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper or compact disc copy of the Sequence Listing is included in the originally-filed specification of the instant application.

The requisite fees, if any, are requested to be charged to Applicant's

Deposit Account No. 14-0116.

Respectfully submitted,

James M. Cate, Reg. No. 25,181

Attorney for Applicant

NASA Johnson Space Center/HA NASA Road One Houston, Texas 77058

Telephone: 281-483-1001 or -4871

Datafax: 281-244-8452

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on

Date

Signature

James M. Cate

**Application No** 

9/532,00<sup>4</sup> PPICARTS COPY

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
-4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: The request to transfer the computer readable form from the parent application 09/056,363 does not comply with the requirements of 37 CFR 1.821(e).
Applicant Must Provide:
An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support Technical Assistance

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY